| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Chief Financial Officer | SVP, Chief Financial Officer
1 company
Labrosse Nicole is a SVP, Chief Financial Officer at HALOZYME THERAPEUTICS, INC.. Recent SEC Form 4 filings include 0 buys and 12 sells.
Estimated insider holdings value: $1.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2025 | HALO Halozyme Therapeutics, Inc. | SVP, Chief Financial Officer | Sell | 2,227 | $77.95 | $173,584.49 | -4.8% | -12.9% | - | |
| Sep 10, 2025 | HALO Halozyme Therapeutics, Inc. | SVP, Chief Financial Officer | Sale+OE | 20,000 | $75.71 | $1,514,267.12 | -24.4% | -18.4% | - | |
| Jul 22, 2024 | HALO Halozyme Therapeutics, Inc. | SVP, Chief Financial Officer | Sale+OE | 5,000 | $53.93 | $269,661.80 | -13.9% | -4.7% | +5.9% | |
| Jun 28, 2024 | HALO Halozyme Therapeutics, Inc. | SVP, Chief Financial Officer | Sale+OE | 30,000 | $51.93 | $1,557,940.00 | -39.2% | +8.8% | -0.3% | |
| Feb 16, 2023 | HALO Halozyme Therapeutics, Inc. | SVP, Chief Financial Officer | Sale+OE | 2,525 | $49.26 | $124,381.50 | -21.8% | -32.1% | -26.7% | |
| Nov 15, 2022 | HALO Halozyme Therapeutics, Inc. | SVP, Chief Financial Officer | Sell | 5,000 | $53.81 | $269,052.55 | -37.2% | -9.1% | -27.2% |